代谢相关脂肪性肝炎药物治疗研究进展与挑战

摘要/Abstract

摘要： 随着肥胖和2型糖尿病(type 2 diabetes mellitus,T2DM)的流行,代谢相关脂肪性肝炎(metabolic dysfunction-associated steatohepatitis,MASH)已成为全球慢性肝病负担的主要病因之一。近年来,MASH药物研发取得了显著进展,候选药物覆盖多条关键靶点和不同通路。MASH临床试验的目标不仅在于改善肝内脂肪沉积与代谢异常,更期望通过逆转肝纤维化、改善炎症,从而降低肝相关不良事件风险,提升患者生活质量。然而,MASH药物开发仍然面临多重挑战。本文系统梳理了目前不同MASH药物的作用机制、关键临床特征和安全性,归纳当前MASH药物研发面临的挑战与瓶颈,并对未来研究方向提出展望。

杨新月, 倪文婧, 陈楠, 李婕. 代谢相关脂肪性肝炎药物治疗研究进展与挑战[J]. 肝脏, 2026, 31(3): 304-311.

/ 推荐

参考文献

[1] Li J, Zou B, Yeo Y H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol. 2019, 4(5):389-398.
[2] Newsome P N, Loomba R. Therapeutic horizons in metabolic dysfunction-associated steatohepatitis[J]. J Clin Invest. 2025;135(13):e186425. Published 2025 Jul 1.
[3] Ledford H. First US drug approved for a liver disease surging around the world[J]. Nature. Published online March 15, 2024.
[4] FDA approves treatment for serious liver disease known as ‘MASH’[EB/OL].[Accessed 2026 February 5]; Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash.
[5] Drygalski K. Pharmacological treatment of MASLD: contemporary treatment and future perspectives[J]. Int J Mol Sci. 2025, 26(13):6518. Published 2025 Jul 7.
[6] Harrison S A, Bedossa P, Guy C D, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6):497-509.
[7] Results from the 52-week phase 2b VOYAGE trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis and fibrosis: a randomized, placebo-controlled trial[J]. Gastroenterol Hepatol (N Y). 2024, 20(12 Suppl 11):13-14.
[8] Noureddin M, Alkhouri N, Lawitz E J, et al. TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial[J]. Nat Med. 2025, 31(7):2297-2305.
[9] Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial[J]. Ann Intern Med. 2016, 165(5):305-315.
[10] Elsayed N A, Mccoy R G, Aleppo G, et al. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes—2025[J]. Diabetes Care. 2025, 48(Supplement_1):S59-S85.
[11] EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)[J]. Obes Facts. 2024,17(4):374-444.
[12] Harrison S A, Thang C, Bolze S, et al. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase Ⅱ randomized placebo-controlled trial (DESTINY-1)[J]. J Hepatol. 2023, 78(5):914-925.
[13] Fabbrini E, Mohammed B S, Korenblat K M, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease[J]. J Clin Endocrinol Metab. 2010, 95(6):2727-2735.
[14] Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther. 2021, 54(10):1263-1277.
[15] Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-alpha/gamma agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial[J]. Hepatology. 2021, 74(4):1809-1824.
[16] Ratziu V, Harrison S A, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator activated receptor α and δ, induces resolution of non-alcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterol. 2016, 150(5):1147-1159.e1145.
[17] Cooreman M P, Vonghia L,Francque S M. MASLD/MASH and type 2 diabetes: two sides of the same coin from single PPAR to pan-PPAR agonists[J]. Diabetes Res Clin Pract. 2024, 212:111688.
[18] Francque S M, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH[J]. N Engl J Med. 2021,385(17):1547-1558.
[19] Sun Y, Wu C, Xin G, et al. Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: a phase Ⅱ, randomized, double-blind, placebo-controlled study[J]. Hepatology. Published online July 28, 2025.
[20] Armstrong M J, Gaunt P, Aithal G P, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet. 2016, 387(10019):679-690.
[21] Sanyal A J, Newsome P N, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis[J]. N Engl J Med. 2025, 392(21):2089-2099.
[22] Zafer M, Tavaglione F, Romero-Gómez M, et al. Review article: GLP-1 receptor agonists and glucagon/GIP/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD[J]. Aliment Pharmacol Ther. 2025, 61(12):1872-1888.
[23] Loomba R, Hartman M L, Lawitz E J, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis[J]. N Engl J Med. 2024, 391(4):299-310.
[24] Noureddin M. MASH clinical trials and drugs pipeline: an impending tsunami[J]. Hepatology. 2025, 82(5):1325-1340.
[25] Concepción-Zavaleta M J, Fuentes-Mendoza J M, Gonzáles-Yovera J G, et al. Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: an updated review[J]. World J Gastroenterol. 2025, 31(37).
[26] Sanyal A J, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis[J]. N Engl J Med. 2024, 391(4):311-319.
[27] Romero-Gómez M, Lawitz E, Shankar R R, et al. A phase Ⅱa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease[J]. J Hepatol. 2023, 79(4):888-897.
[28] Sanyal A J, Kaplan L M, Frias J P, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial[J]. Nat Med. 2024, 30(7):2037-2048.
[29] Abdul Jabbar A B, Naeem U, Zulfiqar K, et al. Highlights of cardiovascular disease prevention studies presented at the 2025 American Heart Association Scientific Sessions[J]. Curr Atheroscler Rep. 2026, 28(1):7. Published 2026 Jan 6.
[30] Sanyal A J, Ratziu V, Loomba R, et al. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis[J]. J Hepatol. 2023, 79(5):1110-1120.
[31] Ratziu V, Harrison S A, Loustaud-Ratti V, et al. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH[J]. J Hepatol. 2023, 78(3):479-492.
[32] Sanyal A J, Lopez P, Lawitz E J, et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial[J]. Nat Med. 2023. 29(2):392-400.
[33] Patel K, Harrison S A, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial[J]. Hepatology. 2020, 72(1):58-71.
[34] Harrison S A, Ruane P J, Freilich B L, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial[J]. Nat Med. 2021, 27(7):1262-1271.
[35] Loomba R, Sanyal A J, Kowdley K V, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH[J]. N Engl J Med. 2023, 389(11):998-1008.
[36] Loomba R, Kowdley K V, Rodriguez J, et al. Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial[J]. Lancet Gastroenterol Hepatol. 2025, 10(8):734-745.
[37] Harrison S A, Abdelmalek M F, Neff G, et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol. 2022, 7(7):603-616.
[38] Loomba R, Bedossa P, Grimmer K, et al. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol. 2024, 9(12):1090-1100.
[39] Mak L Y, Gane E, Schwabe C, et al. A phase Ⅰ/Ⅱ study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis[J]. J Hepatol. 2023, 78(4):684-692.
[40] Sanyal A J, Taubel J, Badri P, et al. Phase Ⅰ randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis[J]. J Hepatol. 2025, 83(4):838-848.
[41] Alkhouri N, Herring R, Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial[J]. J Hepatol. 2022, 77(3):607-618.
[42] Harrison S A, Frias J P, Lucas K J, et al. Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH/MASH and type 2 diabetes in a randomized phase 2 study[J]. Clin Gastroenterol Hepatol. 2025, 23(1):103-113.
[43] Amin N B, Darekar A, Anstee Q M, et al. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase Ⅱ, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic interventions to resolve NASH with fibrosis) study[J]. BMJ Open. 2022, 12(3):e056159.
[44] FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events[EB/OL].[Accessed 2026 February 5]; Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related.
[45] Chen V L, Morgan T R, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance[J]. Hepatology. 2025, 81(1):312-320.
[46] Bansal M B, Patton H, Morgan T R, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance[J]. Hepatology. Published online November 7, 2025.
[47] Bazargan-Hejazi S, Hines C, Usmani M, et al. Racial disparities in mortality rates among patients with hepatic steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis: insights from NHANES Ⅲ data[J]. J Racial Ethn Health Disparities. 2026, 13(2):1083-1093.